Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

slayback pharma llc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. the effectiveness of hydroxyprogesterone caproate injection, usp is based on improvement in the proportion of women who delivered < 37 weeks of gestation. there are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. limitation of use: while there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. it is not intended for use in women with multiple gestations or other risk factors for preterm birth. do not use hydroxyprogesterone caproate injection in women with any of the following conditions: • current or history of thrombosis or thromboembolic disorders • known or suspected breast cancer, other hormone-sensit

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

auromedics pharma llc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. the effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. there are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. limitation of use: while there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. it is not intended for use in women with multiple gestations or other risk factors for preterm birth. do not use hydroxyprogesterone caproate in women with any of the following conditions: - current or history of thrombosis or thromboembolic disorders - known or suspected breast cancer, other hormone-sensitive cancer, or

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

auromedics pharma llc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. the effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. there are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. limitation of use: while there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. it is not intended for use in women with multiple gestations or other risk factors for preterm birth. do not use hydroxyprogesterone caproate in women with any of the following conditions: - current or history of thrombosis or thromboembolic disorders - known or suspected breast cancer, other hormone-sensitive cancer, or

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline extended-release tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline extended-release tablets should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

auromedics pharma llc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate injection, usp is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (stage iii or iv); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation. hydroxyprogesterone caproate is contraindicated in patients with known or suspected carcinoma of the breast, other hormone-sensitive cancer, or history of these conditions; undiagnosed abnormal vaginal bleeding; liver dysfunction or disease; missed abortion, and in those with a history of hypersensitivity to the drug. hydroxyprogesterone caproate is also contraindicated as a diagnostic test for pregnancy and in patients with current or history of thrombotic or thromboembolic disorders.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

mylan institutional llc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. the effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. there are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. limitation of use: while there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. it is not intended for use in women with multiple gestations or other risk factors for preterm birth. do not use hydroxyprogesterone caproate injection in women with any of the following conditions:   hydroxyprogesterone caproate is indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a his

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

lsne, inc - hydroxyprogesterone caproate (unii: 276f2o42f5) (hydroxyprogesterone - unii:21807m87j2) - hydroxyprogesterone caproate injection is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. the effectiveness of hydroxyprogesterone caproate injection is based on improvement in the proportion of women who delivered < 37 weeks of gestation. there are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. limitation of use : while there are many risk factors for preterm birth, safety and efficacy of hydroxyprogesterone caproate injection has been demonstrated only in women with a prior spontaneous singleton preterm birth. it is not intended for use in women with multiple gestations or other risk factors for preterm birth. do not use hydroxyprogesterone caproate injection in women with any of the following conditions: - current or history of thrombosis or thromboembolic disorders - known or suspected breast cancer, other hormone-sens

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

integrated green force, llc - isopropyl alcohol (unii: nd2m416302) (isopropyl alcohol - unii:nd2m416302) -